"Ozempic Usage to Drive 1% GDP Growth, Warns Goldman Sachs"
TL;DR
Goldman Sachs predicts that if 60 million Americans take GLP-1 weight loss drugs like Ozempic by 2028, the US GDP could grow by an additional 1%, attributing this to the economic costs of poor health on labor supply and productivity. The drugs have shown promise in improving health outcomes for patients with type 2 diabetes and obesity, potentially leading to significant spillover effects on the broader economy, including increased productivity and GDP growth in excess of current trends.
Topics:healthhealth-and-economy#glp-1-drugs#health-and-economy#healthcare-innovation#obesity#ozempic#us-economy
- The more Americans that take Ozempic, the faster the US economy will grow, Goldman Sachs says Yahoo Finance
- More Americans taking Ozempic will boost US economy growth outlook Business Insider
- Weight-loss drugs could boost US GDP by 1% in coming years, Goldman says Reuters
- Experts urge doctor oversight as access to weight-loss drugs becomes easier KFSN-TV
- Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs The Guardian US
Want the full story? Read the original reporting
Read on Yahoo Finance